New findings point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer. In everyday life, when things turn out ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ...
The MarketWatch News Department was not involved in the creation of this content. TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech ...
GSK has bolstered its pipeline of small interfering RNA (siRNA) drugs by licensing a potentially first-in-class therapy from China's Suzhou Siran Bio (SiranBio). The therapy, codenamed SA030, is a ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results